VIETNAM PHARMACEUTICAL INDUSTRY

There are about 153 western medicines producing enterprises, 80 traditional medicines producing enterprises, and over 300 establishments producing traditional medicines in 2015. Products of the Vietnam Pharmaceutical Corporation are mostly focused on simple dosage forms, Generic form, low values, overlapping and lack of therapeutic, complex dosage drugs. Generic drugs’ market share was both small and competitive with other businesses. That led to the production and business activities of enterprises inefficient, profit fell and lack of competitiveness.

Vietnam pharmaceutical sector uses about 60,000 tons of pharmaceutical materials , including 80-90% of imported pharmaceutical materials. In particular, China and India are the two countries with the largest export turnover of pharmaceutical materials into Vietnam for many years.

The growth of the prescription drug market will exceed the growth rate of Over-the-counter (OTC) market. According to the Drug Administration of Vietnam – Ministry of Health, the number of drug items re-declared price as of 2/9/2018: the number of drug items with fluctuating price increase/decrease occupies very little (about 0.026%) of the total commercially available drugs.

The biggest wholesale market systems in Vietnam pharmaceutical distribution are Ho Chi Minh City and Hanoi. This is also the primary market that brings fake and low-quality medicines to retailers and customers. Pharmaceutical products are necessities, thus, economic growth virtually has hardly any impact on the industry growth rate. However, specific factors such as raw materials depended on import barriers, technology, technical and many competitors have the strongest impact on the competitiveness and production capacity of the manufacturing enterprises as well as distribution.

To WTO, Vietnamese pharmaceutical market has gradually opened. With wider openness after CPTPP Agreement was signed on March 8th, 2018, the domestic pharmaceutical companies will face greater competition from foreign companies. M&A trend between domestic and foreign enterprises takes place strongly in the form of franchise drug production and the field of distribution. Most of the enterprises of the pharmaceutical industry maintained positive operation with high levels of gross profit and net profit in the period 2016-2017.

0/5 (0 Reviews)
0/5 (0 Reviews)

Abbreviations
Report summary
1. Business environment
1.1. Macroeconomic situation
1.2. Legal framework
1.3. Trade Agreements
2. Pharmaceutical Industry Overview
2.1. Global Pharmaceutical Industry 
2.1.1. Production – Consumption
2.1.2. Export – Import
2.1.3. Production and Consumption Situation in major countries
2.1.4. Large Enterprises in the world
2.2. Vietnam Pharmaceutical Industry Overview
2.2.1. History of Vietnam Pharmaceutical Industry
2.2.2. Industry Position
2.2.3. Industry Scale and Feature
2.2.4. Value Chain of Vietnam Pharmaceutical Industry
2.2.5. Raw materials
2.2.6. Production technology
2.2.7. R&D
2.2.8. Production
2.2.9. Consumption
2.2.10. Export – Import
2.2.11. Price movements
2.2.12. Distribution system
2.3. Risks and challenges
2.4. Industry planning
2.5. Driving forces and forecast
3. Enterprise analysis
3.1. Profitability Ratios
3.2. Cost structure
3.3. Asset Management Ratios
3.4. Capital Structure
3.5. Solvency
3.6. Return on Investment
4. Appendix of financial statements

 

0/5 (0 Reviews)
0/5 (0 Reviews)
DHG Pharmaceutical Joint Stock Company
TRAPHACO Joint Stock Company
Domesco Medical Import Export JSC
Imexpharm Pharmaceutical JSC
OPC Pharmaceutical JSC
S.P.M JSC
Vimedimex Medi – Pharma JSC
Ha Tay Pharmaceutical JSC
Ben Tre Pharmaceutical JSC
Lam Dong Pharmaceutical JSC
0/5 (0 Reviews)
0/5 (0 Reviews)

List of figures
Figure 1: GDP growth, 2011 – 3M/2018
Figure 2: Consumer Price Index for Medicines and Health Services, 2012 – 3M/2018
Figure 3: VND/USD exchange rate, 3/2016 – 3/2018
Figure 4: VND/CNY exchange rate, 2016 – 3/2018
Figure 5: Population and population growth, 2006 -2017
Figure 6: Population structure, 1999 – 2016
Figure 7: Pharmaceuticals imports ,2012 – 3M/2018e
Figure 8: Global spending on medicines, 2010 – 2016e
Figure 9: World sales of prescription drugs, 2010 – 2016
Figure 10: Consumption structure by types of medicines, 2011 – 2016
Figure 11: Consumption market share by group, 2016
Figure 12: World’s top 10 consumed phamaceuticals, 2016
Figure 13: Global pharmaceutical exports, 2010 – 2017e
Figure 14: Top 10 pharmaceutical enterprises with largest revenue, 2017
Figure 15: Classification of medicine markets by distribution methods
Figure 16: Classification of medicine markets by ownership
Figure 17: Pharmaceutical materials imports, 2012 – 3M/2018e
Figure 18: Pharmaceutical materials imports, 3M/2017 – 3M/2018e
Figure 19: Ratio of R&D/revenue at major pharmaceutical companies in the world, 2016
Figure 20: Domestic pharmaceutical production value, 2010 – 2017e
Figure 21: Pharmaceutical market value, 2010 – 2017e
Figure 22: Value ratio of domestically produced medicines in Vietnam, 2010 – 2017e
Figure 23: Domestically produced medicine consumption, 2010 – 3M/2018e
Figure 24: Spending on medicines in Vietnam, 2009 – 2017e
Figure 25: Spending on medicines per capita in some countries, 2016e
Figure 26: Medicines consumption structure by channel, 2010 – 2017e
Figure 27: Market value of prescription  drugs (ETC), 2011 – 2017e
Figure 28: Market value of non-presciption drugs (OTC), 2010 – 2017e
Figure 29: Patened drugs (Patent), 2010 – 2017e
Figure 30: Generic drug market, 2010 – 2017e
Figure 31: Pharmaceutical imports, 2012 – 3M/2018e
Figure 32: Pharmaceutical imports, 3M/2017 – 3M/2018e
Figure 33: Pharmaceutical exports, 2012 – 3M/2018
Figure 34: Export structure by country, 3M/2018
Figure 35: Rate of drug re-price (increase), 2013 – 2016
Figure 36: Drugs distribution network in Vietnam
Figure 37: Top pharmaceuticals distribution enterprise by revenue, 2016
Figure 38: Outstanding distribution chain business results, 2016
Figure 39: Unqualified sample ratio, 2010 – 2016e
Figure 40: Total healthcare expenses, 2010 – 2016f
Figure 41: Population tower, 2016
Figure 42: Over-60 population growth in the world, 1950 – 2050
Figure 43: M&A of pharmaceutical industry, 2010 – 2016
Figure 44: The revenue of top drugs in developed countries, 2018
Figure 45: The revenue of top drugs in developing countries, 2018
Figure 46: The growth of total drug consumption and average drug spending per capita, 2010-2020f
Figure 47: Profitability, 2016 – 2017
Figure 48: COGS/NR, 2016 – 2017
Figure 49: Selling expenses, 2016 – 2017
Figure 50: Administrative expenses, 2016 – 2017
Figure 51: Days in inventory, 2016 – 2017
Figure 52: Days of sales outstanding, 2016 -2017
Figure 53: Asset turnover
Figure 54: Self-financing ratio, 2016 – 2017
Figure 55: Solvency, 2016 – 2017
Figure 56: Profit ratio, 2016 – 2017
List of tables
Table 1: Pharmaceuticals exporters, 2017
Table 2: Pharmaceuticals importers, 2017
Table 3: General information about the healthcare industry of The U.S, 2016e
Table 4: General information about the healthcare industry of Japan, 2016e
Table 5: General information about the healthcare industry of China, 2016e
Table 6: General information about the healthcare industry of Germany, 2016e
Table 7 General information about the healthcare industry of France, 2016e
Table 8: Origin of machinery and equipments of a number of large pharmaceutical companies
Table 9 Some major machineries in pharmaceutical manufacturing line
Table 10: Medicine production by type, 2013 – 3M/2018e
Table 11: Vietnam’s top import partners, 3M/2018
Table 12: Top exporting enterprises, 3M/2018
Table 13: Price movements of some major drugs in the market, 12/2016 – 3/2018
Table 14: The difference in the price of some drugs at some drug stores, 2017
Table 15: The number of medical facilities, 2010 – 2016
Table 16: Typical chain of pharmacies, 2016
Table 17: Average cost of R&D to produce new drugs (USD million)
Table 18: 10 typical pharmaceutical enterprises in 2017

0/5 (0 Reviews)
0/5 (0 Reviews)